title: Significance of CD4 T-cell adenosine triphosphate levels monitoring in elderly renal transplant recipients.
abstract: OBJECTIVE
  To find the significance of CD4 T-cell adenosine triphosphate (ATP) levels in elderly renal recipients in correlation with drug doses, levels, and clinical parameters.
  
  
  METHODS
  Drug doses and levels, CD4 T-cell ATP level (162 sequential samples), and other clinical data were collected and assessed among 31 elderly renal recipients who underwent transplantations from November 2007 to March 2011.
  
  
  RESULTS
  Among subjects with stable clinical status, the main ATP levels pretransplantation were not significantly different from those posttransplantation: 302.4 ± 97.5 ng/mL versus 288.8 ± 102.6 ng/mL (P > .05). There was no relationship between ATP levels and tacrolimus concentrations or doses. In 12 patients experiencing infection, the ATP levels were significantly lower then those of subjects showing a stable clinical status: 127.3 ± 92.8 versus 288.8 ± 102.6 ng/mL (P < .01). Six patients with biopsy-proven acute rejection episodes did not show significantly higher ATP levels compared with those who were clinically stable: 26.2 ± 224.8 versus 288.8 ± 102.6 (P > .05).
  
  
  CONCLUSIONS
  CD4 T-cell ATP levels were valuable to monitor immunosuppression among elderly renal transplant recipients.
authors.affiliation: Organ Transplant Institute, Fuzhou General Hospital, Xiamen University, Fuzhou, PR China.
authors.forename: Z
authors.initials: Z
authors.lastname: Wu
authors.forename: H
authors.initials: H
authors.lastname: Zhou
authors.forename: S
authors.initials: S
authors.lastname: Yang
authors.forename: J
authors.initials: J
authors.lastname: Cai
authors.forename: Q
authors.initials: Q
authors.lastname: Wang
authors.forename: L
authors.initials: L
authors.lastname: Liao
authors.forename: J
authors.initials: J
authors.lastname: Tan
mesh_terms: D000208:Acute Disease; D000255:Adenosine Triphosphate / Q000097:blood*; D000367:Age Factors; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D003141:Communicable Diseases / Q000097:blood / Q000276:immunology; D016903:Drug Monitoring; D005260:Female; D006084:Graft Rejection / Q000097:blood / Q000276:immunology / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D015166:Monitoring, Immunologic; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D007166:Immunosuppressive Agents; D000255:Adenosine Triphosphate